ESC 365 - Liraglutide and empagliflozin – An evaluation of benefits.

ESC Premium Access

Liraglutide and empagliflozin – An evaluation of benefits.

Session: Treatment of type 2 diabetes - Important new aspects for the cardiologist

Topic: Drug therapy

Speaker: Associate Professor T. Schmidt (Copenhagen, DK)

Event: ESC Congress 2017

Congress Presentation

About the speaker

Associate Professor Thomas Andersen Schmidt

Bispebjerg University Hospital, Copenhagen (Denmark)

1 presentation

0 follower

3 more presentations in this session

Treatment aims of glucose lowering drugs in patients with type 2 diabetes

Speaker: Professor L. Ryden (Stockholm, SE)

Rethinking the appraisal and approval of drugs for type 2 diabetes.

Speaker: Professor A. Tsapas (Thessaloniki, GR)

Is type 2 diabetes a category error - How about treating the elderly?

Speaker: Professor G. Schernthaner (Vienna, AT)

Access the full session

Treatment of type 2 diabetes - Important new aspects for the cardiologist

Speakers: Associate Professor T. Schmidt, Professor L. Ryden, Professor A. Tsapas, Professor G. Schernthaner

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

Related content

Open Access

Mode of intervention in aortic stenosis.

28 August 2021

ESC Premium Access

Cardiovascular benefit of lowering LDL-C below 1 mmol/L (40 mg/dl)

28 August 2021

ESC Premium Access

Will coronary atherosclerosis be eliminated?

27 August 2021

ESC 365 is supported by